

Note: This document has been translated from the Japanese original version for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original version, the original version shall prevail. PeptiDream Inc. assumes no responsibility for this translation or for direct, indirect or any other forms of damage arising from the translation.

(Stock Exchange Code: 4587)

March 3, 2026

(Commencement of electronic provision: March 2, 2026)

To Shareholders with Voting Rights:

Patrick Reid
Representative Director, President & CEO
PeptiDream Inc.
3-25-23 Tonomachi, Kawasaki-ku,
Kawasaki City, Kanagawa

**NOTICE OF
THE 20th ORDINARY GENERAL MEETING OF SHAREHOLDERS**

Dear Shareholders:

We would like to express our appreciation for your continued support and patronage.

You are cordially notified of the 20th Ordinary General Meeting of Shareholders of PeptiDream Inc. (the “Company”). The meeting will be held for the purposes as described below.

In convening this meeting, the Company has taken electronic provision measures, and posted the matters subject to electronic provision measures on the following Company’s website on the Internet.

PeptiDream’s website

<https://www.peptidream.com/en/ir/stock-information/shareholders-meeting-related-presentations/>

In addition to the above, the information is also posted on the following website on the Internet

Tokyo Stock Exchange’s website

<https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show>

Please access the Tokyo Stock Exchange’s website above. Enter or search for our company name “PeptiDream” or Stock Exchange Code “4587,” and select “Basic information” and “Documents for public inspection/PR information” in that order.

If you exercise your voting rights in writing or via the Internet, etc., please review the Reference Documents for the General Meeting of Shareholders posted on the matters subject to electronic provision measures, and exercise your voting rights by 6:00 p.m. on Tuesday, March 24, 2026, Japan time.

- 1. Date and Time:** Wednesday, March 25, 2026 at 10:00 a.m. Japan time (reception desk opens at 9:15 a.m.)
- 2. Place:** Congr s Square Haneda (Zone J, Haneda Innovation City)
1-1-4 Haneda Airport, Ota-ku, Tokyo
Refer to the “Map to the Venue of the General Meeting of Shareholders” at the end of this document for details. Note that the venue is different from last year.
- 3. Agenda:**
- Matters to be reported:**
1. Business Report, Consolidated Financial Statements, and Results of Audit Reports of the Consolidated Financial Statements by the Accounting Auditor and the Audit and Supervisory Committee for the Company’s 20th Fiscal Year (January 1, 2025–December 31, 2025)
 2. Non-consolidated Financial Statements for the Company’s 20th Fiscal Year (January 1, 2025–December 31, 2025)
- Proposals to be resolved:**
- Proposal:** Election of 2 Directors (Excluding Directors Appointed as Audit and Supervisory Committee Members)

No.	Name (Date of birth)	Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held (Of which, number of those to be delivered by the share benefit trust)
2	Masato Murakami (March 26, 1974) (New appointment)	<p>April 2004 Fellow of Division of Genetics, The Institute of Medical Science, The University of Tokyo</p> <p>July 2006 Assistant Professor of Division of Genetics, The Institute of Medical Science, The University of Tokyo</p> <p>April 2007 Research Fellow of IFOM, The FIRC Institute of Molecular Oncology Foundation</p> <p>August 2010 Group Leader of Molecular Oncology Pathology of Novartis Institutes for Biomedical Research, Novartis Pharma AG.</p> <p>October 2016 Executive Medical Director of R&D Division of Daiichi Sankyo Company, Limited</p> <p>April 2017 Vice President of Biomarker Promotion Department and Global Precision Medicine Department, R&D Division of Daiichi Sankyo Company, Limited</p> <p>January 2022 Chief Medical Officer (CMO) of the Company (to present)</p> <p>July 2024 President and Representative Director of PDRadiopharma Inc. (to present)</p> <p>December 2024 Director of PeptiAID Inc.</p> <p>March 2025 President and Representative Director of PeptiAID Inc. (to present)</p>	500 (-)

(Notes)

- None of the above candidates has special interest in the Company.
- Dr. Patrick Reid joined the Company shortly after its foundation and has been leading research and development operations. He is assuming the responsibility of management as a Director of the Company and has deep insight and ability. In light of this, the Company believes that Dr. Reid is capable of successfully fulfilling his duties as Director, with respect to the decision-making process of the Board of Directors.
- Dr. Masato Murakami has been leading new medicine development as the Company's CMO, and, as President and Representative Director of PDRadiopharma Inc., the Company's subsidiary, has been leading its business operations. In light of this, the Company believes that Dr. Murakami is capable of successfully fulfilling his duties as Director by utilizing his experience and insight, with respect to the decision-making process of the Board of Directors.
- The Company has concluded a directors and officers liability insurance (D&O insurance) contract that insures all directors in order to allow the officers to fulfill their expected roles when performing their duty and to enable the Company to attract talented human resources. If this proposal is approved as originally proposed and the candidates assume office as Directors, each candidate shall be an insured person under this contract. Under this contract, any damage that may arise as a result of the insured officers assuming responsibilities related to the performance of their duties or receiving claims pertaining to the pursuit of such responsibilities shall be covered. However, there are certain exemptions where no damage shall be covered if such damage was caused as a result of acts committed while being aware of violation of laws and regulations. The Company bears all insurance premiums, including the portion for riders, and the insured persons shall not effectively bear any insurance premiums. The Company intends to update this contract on March 28, 2026 during the candidates' terms of office.

(Reference)

The structure and the skill matrix of the Board of Directors in case the proposal is approved as originally proposed in this Ordinary General Meeting of Shareholders are as follows.

Structure and Skill Matrix of the Board of Directors:

Name/Position	Composition of the Committees Members				Growth drivers (offensive)			Strengthen business foundation (defensive)			Sustainability
	Audit and Supervisory Committee	Nomination and Remuneration Committee	Sustainability and Governance Committee	Compliance Risk Management Committee	Corporate Management	Global Business	Technology & R&D	Finance & Accounting	HR Management & Development	Legal & Risk Management	
Patrick Reid Representative Director, President, CEO Male		●	●		◎	◎	◎		○	○	
Masato Murakami Director, EVP Radiopharmaceuticals Business Male				●	○	◎	◎	○		○	
Kiichiro Kamiya Outside Director (Full-Time Audit and Supervisory Committee Member) Independent Outside Male	●	●		●	◎	◎	○		○		
Yukinori Hanafusa Outside Director (Audit and Supervisory Committee Member) Independent Outside Male	●	●	●		○			◎	○		○
Junko Utsunomiya Outside Director (Audit and Supervisory Committee Member) Independent Outside Female	●	●		●	○				○	◎	○
Junko Nishiyama Outside Director (Audit and Supervisory Committee Member) Independent Outside Female	●	●	●		○		○			○	◎

(Notes)

1. The matrix above indicates up to five main skills of the executive directors, and up to four main skills of the outside directors. It does not represent all the skills possessed by each director.
2. “◎” in the table above refers to the skill with particularly high expertise and deep experience, and “○” refers to the skill with adequate knowledge and experience. “Independent” means the independent director registered with the securities exchange.